Claude for Healthcare & Life Sciences

Anthropic offers BAA terms with enterprise customers covering Claude deployments touching PHI. NINtec's healthcare engagements include the BAA negotiation, audit-log retention configuration, and minimum-necessary-PHI handling design that operationalises HIPAA compliance. The model itself is one component; the deployment posture is what makes the system compliant.

Technically yes via tool-use integrations; clinically and legally, write-back is gated on clinical review and informed consent in most workflows. Our clinical-summary deployments draft summaries that clinicians edit and approve before chart-write; our prior-auth deployments draft the packet for staff finalisation. Direct unattended write-back is reserved for low-risk operational data with explicit governance.

Epic (most common), Cerner, Athenahealth, Meditech, eClinicalWorks. The integration pattern uses HL7 FHIR R4 APIs where the EHR exposes them, plus point-to-point integration for write-paths the FHIR endpoints do not cover.

Claude deployments that constitute or support medical-device software fall under 21 CFR Part 11 obligations — electronic-records, electronic-signatures, audit trails, and validation. Our medical-device engagements integrate Part 11 controls from architecture phase, with formal validation cycles before any production release.

Pharmacovigilance Claude deployments process adverse-event narratives at scale, structure unstructured text for safety review, and flag case clusters meeting predefined signal thresholds. The clinical-safety reviewer remains the decision authority — Claude is a force multiplier, not an autonomous classifier in regulatory submissions.

No. Anthropic enterprise terms include explicit no-training-on-customer-data provisions. We negotiate the specific addendum your compliance team needs, and configure data-handling so the Claude API call is the boundary — no accidental retention beyond the operationally required logs.

It depends on the deployment definition. CDS that surfaces relevant guidance to a clinician who decides — yes, with clinical validation. CDS that constitutes regulated software-as-a-medical-device — yes, but with the FDA / CE regulatory pathway followed end-to-end. Our Discovery phase identifies the regulatory classification before engineering begins.

14–22 weeks from engagement to first production region for typical clinical-workflow deployments. Drug-discovery and pharmacovigilance engagements vary more widely. Engagements involving FDA-regulated medical-device software typically run longer because the regulatory pathway is the long pole.